Bulletin
Investor Alert

Corbus Pharmaceuticals Holdings Inc.

NAS: CRBP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 27, 2021, 7:59 p.m.

/zigman2/quotes/201549545/composite

$

2.00

Change

+0.05 +2.56%

Volume

Volume 751,999

Quotes are delayed by 20 min

/zigman2/quotes/201549545/composite

Today's close

$ 1.97

$ 1.95

Change

-0.02 -1.02%

Day low

Day high

$1.81

$2.17

Open

52 week low

52 week high

$0.91

$9.78

Open

Company Description

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, ...

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Valuation

Price to Sales Ratio

9.65

Price to Book Ratio

57.35

Enterprise Value to Sales

9.04

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

256,337.00

Income Per Employee

-506,764.00

Receivables Turnover

26.96

Total Asset Turnover

0.75

Liquidity

Current Ratio

1.09

Quick Ratio

1.09

Cash Ratio

0.91

Profitability

Operating Margin

-226.01

Pretax Margin

-210.37

Net Margin

-197.69

Return on Assets

-148.66

Return on Equity

-424.29

Return on Total Capital

-375.38

Return on Invested Capital

-342.06

Capital Structure

Total Debt to Total Equity

153.40

Total Debt to Total Capital

60.54

Total Debt to Total Assets

19.22

Long-Term Debt to Equity

131.50

Long-Term Debt to Total Capital

51.89

Officers and Executives

Name Age Officer Since Title
Dr. Yuval Cohen 44 2013 Chief Executive Officer & Director
Mr. Sean F. Moran 61 2014 Chief Financial & Accounting Officer
Dr. Barbara White 68 2014 Chief Medical Officer
Dr. Sergei Atamas - 2019 Executive Director-Research
Mr. Craig Millian 51 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/21/2020 Sean F. Moran
Chief Financial Officer
87,500   Disposition at $1.75 per share. 153,125
12/21/2020 Sean F. Moran
Chief Financial Officer
87,500   Derivative/Non-derivative trans. at $1.4 per share. 122,500
12/18/2020 Sean F. Moran
Chief Financial Officer
53,610   Disposition at $1.4 per share. 75,054
12/18/2020 Sean F. Moran
Chief Financial Officer
53,610   Derivative/Non-derivative trans. at $1 per share. 53,610
12/16/2020 Sean F. Moran
Chief Financial Officer
36,923   Disposition at $1.32 per share. 48,738
12/16/2020 Sean F. Moran
Chief Financial Officer
36,923   Derivative/Non-derivative trans. at $0.17 per share. 6,276
11/11/2020 Yuval Cohen
Chief Executive Officer; Director
4,240   Acquisition at $1.21 per share. 5,130
03/17/2020 Barbara White
Chief Medical Officer
15,606   Acquisition at $3.63 per share. 56,649
03/17/2020 Yuval Cohen
Chief Executive Officer; Director
4,300   Acquisition at $3.49 per share. 15,007
03/17/2020 Robert Discordia
Chief Operating Officer
2,840   Acquisition at $3.54 per share. 10,053
03/17/2020 Craig Millian
Chief Commercial Officer
2,000   Acquisition at $4.25 per share. 8,500
11/12/2019 Barbara White
Chief Medical Officer
3,424   Acquisition at $4.38 per share. 14,997
11/12/2019 Yuval Cohen
Chief Executive Officer; Director
1,430   Acquisition at $4.26 per share. 6,091
11/11/2019 Robert Discordia
Chief Operating Officer
2,500   Acquisition at $4.62 per share. 11,550
11/11/2019 Craig Millian
Chief Commercial Officer
1,000   Acquisition at $4.38 per share. 4,380
08/15/2019 Craig Millian
Chief Commercial Officer
1,500   Acquisition at $5.48 per share. 8,220
08/12/2019 Barbara White
Chief Medical Officer
1,639   Acquisition at $6.1 per share. 9,997
08/12/2019 Yuval Cohen
Chief Executive Officer; Director
1,175   Acquisition at $6.06 per share. 7,120
08/12/2019 Robert Discordia
Chief Operating Officer
15,000   Acquisition at $5.86 per share. 87,900
08/12/2019 Craig Millian
Chief Commercial Officer
1,500   Acquisition at $6 per share. 9,000
05/17/2019 Barbara White
Chief Medical Officer
1,389   Acquisition at $7.2 per share. 10,000
/news/latest/company/us/crbp

MarketWatch News on CRBP

  1. Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market

    5:06 p.m. Dec. 11, 2020

    - MarketWatch Automation

  2. Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market

    5:16 p.m. Nov. 27, 2020

    - MarketWatch Automation

  3. Corbus Pharmaceuticals Holdings Inc. stock rises Monday, outperforms market

    5:02 p.m. Nov. 23, 2020

    - MarketWatch Automation

  4. Loading more headlines...
/news/nonmarketwatch/company/us/crbp

Other News on CRBP

  1. IBM, GSAT among premarket losers

    8:29 a.m. Jan. 22, 2021

    - Seeking Alpha

  2. AJRD, AJIO, NK and LAZR among premarket gainers

    8:26 a.m. Dec. 21, 2020

    - Seeking Alpha

  3. Cannabis Stocks Are Hot Again And Here Are Some You Should Buy

    3:57 p.m. Dec. 14, 2020

    - Seeking Alpha

  4. BB, MRNA, LI and LYG among premarket gainers

    8:24 a.m. Dec. 1, 2020

    - Seeking Alpha

  5. Corbus Pharmaceuticals (CRBP) Gets a Hold Rating from Oppenheimer

    10:45 p.m. Nov. 10, 2020

    - SmarterAnalyst

  6. Corbus Pharmaceuticals down 4% after Q2 miss; top-line down 52%

    9:04 a.m. Nov. 10, 2020

    - Seeking Alpha

  7. Corbus Pharmaceuticals EPS misses by $0.02, misses on revenue

    7:08 a.m. Nov. 10, 2020

    - Seeking Alpha

  8. 10-Q: CORBUS PHARMACEUTICALS HOLDINGS, INC.

    5:08 p.m. Nov. 9, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  9. Corbus's lenabasum shows benefit in autoimmune disorder

    10:35 a.m. Nov. 9, 2020

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive

Second floor

Norwood, Massachusetts 02062

Phone

1 6179630100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$36.14M

Net Income

$-71.45M

2019 Sales Growth

649.5%

Employees

141.00

/news/pressrelease/company/us/crbp

Press Releases on CRBP

  1. The Little-Known Tech That Could Transform Healthcare

    8:06 a.m. Jan. 19, 2021

    - Financial News Media

  2. The Little-Known Tech That Could Transform Healthcare

    8:00 a.m. Jan. 19, 2021

    - PR Newswire - PRF

  3. Top Penny Stocks To Watch Right Now; 5 Biotech Stocks To Know

    12:08 p.m. Nov. 12, 2020

    - Penny Stocks

  4. Do Smaller Marijuana Stocks Hold More Value?

    4:27 p.m. Oct. 25, 2020

    - Marijuana Stocks

  5. Loading more headlines...
Link to MarketWatch's Slice.